Related Experiment Videos
LY164846 in vitro antimicrobial activity testing, including disk diffusion susceptibility tests using 30-microgram
Antimicrobial Agents and Chemotherapy
|March 1, 1986
Summary
A novel oral cephalosporin, LY164846, demonstrates a specific antimicrobial spectrum effective against certain bacteria like Staphylococcus and Streptococcus. Laboratory testing using cephalothin may be a viable alternative for LY164846.
Area of Science:
- Microbiology
- Pharmacology
Background:
- A new oral cephalosporin, LY164846, has been developed.
- Understanding its antimicrobial spectrum is crucial for clinical application.
Purpose of the Study:
- To define the antimicrobial spectrum of LY164846.
- To evaluate the utility of cephalothin for laboratory testing of LY164846.
Main Methods:
- In vitro susceptibility testing of LY164846 against various bacterial species.
- Comparison of LY164846 activity with cephalothin disk diffusion and dilution methods.
Main Results:
- LY164846 exhibited activity against methicillin-susceptible Staphylococcus spp., streptococci (excluding Enterococcus), Haemophilus influenzae, Branhamella catarrhalis, and some anaerobes.
- Enterobacteriaceae, Pseudomonas spp., Acinetobacter spp., enterococci, and some strains of Staphylococcus haemolyticus and Bacteroides fragilis were resistant.
- Cephalothin testing can potentially represent LY164846 if breakpoints are adjusted.
Conclusions:
- LY164846 possesses a distinct antimicrobial profile.
- Cephalothin may serve as a surrogate for laboratory susceptibility testing of LY164846 within its defined spectrum.